Pavitra Sirolkar’s son Arav has Allan-Herndon-Dudley syndrome. She had to arrange around ₹12–13 lakh for one month’s supply of tiratricol from Germany. Commercial treatment could cost ₹4.68 crore to ₹9 crore per child annually. Dr Sivaranjani Santosh helped bring attention to this gap. A specially compounded formulation is estimated at ₹2.5 lakh per child for a year. Seven children are expected to receive the medicine free, with handover planned for November 30, 2026.
For the family, the expense was not a one-time obstacle but a recurring demand tied to a child’s continuing care. The doctor explored options with paediatricians, endocrinologists and paediatric neurologists before the public appeal brought wider attention to the case. Her involvement helped turn one family’s urgent request into a coordinated search for a practical supply arrangement.
A Mother’s Search for Treatment Exposed an Impossible Price
Arav’s diagnosis placed his family in a difficult position. His mother, Pavitra, had to find a way to continue treatment despite the extraordinary cost of importing tiratricol. One month’s supply from Germany required approximately ₹12–13 lakh, making long-term treatment difficult to sustain. Dr Sivaranjani Santosh was treating Arav and became involved as the family searched for a reliable supply.
Initial efforts to obtain the medicine through the manufacturer’s compassionate-use programme did not succeed. The problem highlighted a wider challenge. Families may spend months seeking a diagnosis, only to discover that a treatment exists but remains unaffordable. The case prompted the doctor to seek help from organisations working on access to medicines.
Understanding the Rare Condition and the Role of Tiratricol
Allan-Herndon-Dudley syndrome is also called MCT8 deficiency. It is a rare genetic disorder linked to changes in the SLC16A2 gene. This gene helps produce a transporter that carries thyroid hormones into cells, including brain cells. When the transporter fails, the brain cannot receive these hormones normally. Abnormal hormone levels can also affect other parts of the body. Children may experience developmental delays, low muscle tone, movement difficulties and feeding problems.
Tiratricol, also known as TRIAC, is a thyroid hormone analogue used to manage effects associated with MCT8 deficiency. It is not a cure, and children need continuing care from experienced specialists. The condition is associated with impaired brain development and can affect several aspects of a child’s daily life. Diagnosis and management involve specialist teams, including paediatric neurologists and endocrinologists. Few diagnosed patients can make information, expertise and treatment harder to access.
How International Cooperation Brought the Cost Down
Earlier procurement efforts failed. Dr Sivaranjani Santosh then took the issue to social media in September 2026. Her appeal asked people to draw government representatives’ attention to the families’ difficulties. The case reached the Netherlands-based Pharmaceutical Accountability Foundation (PAF), which explored preparing the medicine through pharmaceutical compounding. Transvaal Pharmacy in The Hague developed a formulation using the active pharmaceutical ingredient. The commercial version costs several crores annually. The compounded formulation is estimated at around ₹2.5 lakh per child.
Access to Medicines India, including K.M. Gopakumar, helped coordinate the effort, while medical professionals assisted in identifying other children. This was not a simple price discount from the original manufacturer. It was a separate compounding route supported by an organisation focused on medicine access. The foundation’s involvement connected the family-level problem with a pharmacy able to prepare the medicine. Different groups handled separate responsibilities. These included funding, medical coordination, permissions and delivery.
Seven Children Are Set to Receive a Year’s Supply Free
Dr Sivaranjani Santosh and her partners identified seven children. They include Arav and five patients identified at Christian Medical College (CMC), Vellore. A seventh child’s father contacted the doctor after seeing her appeal. One year’s treatment for all seven is estimated to cost €14,200, or approximately ₹15.08 lakh. Around ₹6.09 lakh was raised in India, while PAF undertook to raise the remaining amount in the Netherlands. The medicine will be provided free, so the parents will not pay for this year’s supply.
The Organization for Rare Diseases India helped families obtain individual import permissions. Pavitra also supported other parents with the paperwork. The funding plan covers one full year of treatment. Families will receive the medicine in two shipments. The medicine has a shelf life of around six months, making this schedule necessary. Recent reports say it has reached India through the required channels, with handover planned for November 30, 2026. The import approvals cover each patient separately. They do not create an unrestricted commercial supply.
The Wise Take
The arrangement is a major step. However, importing medicine for a limited group cannot solve the wider access problem. Current permissions are patient-specific and intended for personal use. They do not automatically allow bulk import of the active ingredient or commercial manufacturing in India. Dr Sivaranjani Santosh wants domestic compounding to be explored so children can obtain treatment more reliably. Access to Medicines India is also examining whether Indian companies could compound the medicine.
The doctor has been sharing information with specialists to help locate more patients, although there is no confirmed national count. Reducing costs for these seven children does not end the work. It is, however, a meaningful beginning. The next goal is a safe, sustainable and affordable pathway for more families across India. Any move towards domestic preparation would still need appropriate quality controls, regulatory oversight and specialist guidance. A lower price alone is not enough; families also need a dependable supply and confidence in the medicine’s quality. The campaign has opened a wider discussion. India must consider how to meet the needs of people living with very rare conditions.
Also read our other article on Subhash Ahirwar: From Childhood Poverty to Theatre and Screen Acting, His Journey Takes a New Turn After India’s Got Latent
Follow The Wise Indian for regular updates on stories that shape India’s strategic future and global standing. Stay connected with us for sharp analysis, untold perspectives, and a closer look at the shifting legal landscapes, civic rights, and institutional frameworks defining our democratic fabric.